Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, research and development-driven biopharmaceutical company headquartered in Tokyo, Japan. Founded in 1781, Takeda's core business involves the research, development, manufacturing, and commercialization of innovative biopharmaceutical products. Its mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine.

The company focuses on delivering transformative treatments across several key therapeutic areas, including oncology, rare diseases, neuroscience, gastroenterology and inflammation, plasma-derived therapies, and vaccines. Notable products in its portfolio include Entyvio for inflammatory bowel diseases, Vyvanse/Elvanse for ADHD, and Takhzyro for rare genetic conditions, which are among its top-selling drugs.

In recent leadership changes, Julie Kim was appointed Representative Director, President, and CEO in June 2026, succeeding Christophe Weber. Takeda continues to advance its pipeline, with recent news including positive Phase 3 study data for zasocitinib in psoriasis and oveporexton for narcolepsy type 1. The company also announced a strategic collaboration with Insilico Medicine in July 2026 to leverage AI for drug discovery. Takeda maintains a significant global presence, operating in approximately 80 countries, and solidified its position as a leading biopharmaceutical company following its 2019 acquisition of Shire, which expanded its focus on rare genetic disorders and immunology.